Work

Comparative outcomes of first-line atezolizumab plus bevacizumab (A+B) and durvalumab plus tremelimumab (D+T) in hepatocellular carcinoma (HCC).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.4163

Authors: Sarina Ailawadi, Jennifer Elizabeth Murphy, Michael H. Storandt, Rohit Rao, Amit Mahipal

Institutions: University Hospitals of Cleveland, Case Western Reserve University, University Hospitals Cleveland Medical Center, Mayo Clinic, University Hospitals Seidman Cancer Center

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162500792

Cites:

Cited by:

Related to: